Differential Prox-1 / CD 31 expression in lesions and tumors

Lymphangiogenic Gene Therapy, yellow nail syndrome, lymphatic vascular development, Intratumoral lymphatics, peritumoral lymphatics, stem cell research, Angiopoietins, VEGF, PIGF, FOXC1, FOXC2, Lymphatic Insufficiency. SOX18, lymphatic hyperplasia, Molecular lymphangiogenesis, PROX1, FLT3, Telan­giectasia, Lymphatic endothelial cells, adult vasculogenesis, LYVE1

Moderators: Birdwatcher, jenjay, Cassie, patoco, Senior Moderators

Differential Prox-1 / CD 31 expression in lesions and tumors

Postby patoco » Wed Sep 20, 2006 1:20 pm

Differential Prox-1 and CD 31 expression in mucousae, cutaneous and soft tissue vascular lesions and tumors.


Reis RM, Reis-Filho JS, Longatto Filho A, Tomarev S, Silva P, Lopes JM.

Life and Health Sciences Research Institute (ICVS), School of Health
Sciences, University of Minho, Braga, Portugal.

The study of lymphatic vessels and lymphatic tumors has been hampered
with difficulty due to the overlapping morphological features between
blood and lymphatic endothelial cells, as well as to the lack of
specific lymphatic endothelial markers. Over the last few years,
lymphatic vessels and lymphangiogenesis have received great attention
owing to their putative implications in terms of metastatic
dissemination and the promise of targets for lymphangiogenic therapy.
Prox-1 is a nuclear transcription factor that plays a major role during
embryonic lymphangiogenesis and is deemed to be a useful marker for
differentiating lymphatic endothelial cells from the other blood
vessels endothelial cells. Here, we describe a double-immunostaining
strategy for formalin-fixed, paraffin-embedded tissues that aims at
evaluating the distribution of Prox-1 and CD 31 - a cytoplasmic
pan-endothelial marker - in a series of 28 mucousae, cutaneous and soft
tissue vascular lesions and tumors, including hemangiomas,
lymphangiomas, lymphangiectasia, and Kaposi's sarcomas. Our results
showed that in non-lesional mucousae and skin, Prox-1 decorated
exclusively the nuclei of endothelial cells in lymphatic vessels.
Prox-1 stained almost all the benign lymphatic vascular lesions/tumors
(91%) and was absent or only focally positive in 75% of blood vascular
tumors. CD 31 stained endothelial cells of blood vessels of superficial
and deep dermal plexuses, lymphatics, and all blood vascular
lesions/tumors. Kaposi's sarcomas were all positive for both CD 31 and
Prox-1 markers. In conclusion, although Prox-1 expression in vascular
lesions/tumors was not entirely restricted to tumors with known
lymphatic differentiation, CD 31/Prox-1 double-immunolabeling can be
used as an adjunct marker to identify lymphatic vessels in routinely
processed formalin-fixed, paraffin-embedded samples.

PMID: 16308102 [PubMed - indexed for MEDLINE]

http://www.ncbi.nlm.nih.gov/entrez/quer ... etrieve&...


Lymphedema People

User avatar
Site Admin
Posts: 2175
Joined: Thu Jun 08, 2006 9:07 pm

Return to Genetics, Research, Lymphangiogenesis, Angiogenesis

Who is online

Users browsing this forum: No registered users and 3 guests